This is a drug monograph from the BSAVA Small Animal Formulary Part A: Canine and Feline. BSAVA members should login for access to the full monograph. Non-members can join BSAVA, buy a Formulary subscription, or buy the printed edition.
Fernandez R and Chon E (2018) Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs. Journal of Veterinary Internal Medicine32, 1060–1069
Mastromauro ML, Suter SE, Hauck ML and Hess PR (2018) Oral melphalan for the treatment of relapsed canine lymphoma. Veterinary Comparative Oncology16, 123–129
Alvarez FJ, Kisseberth WC, Gallant SL and Couto CG (2006) Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.Journal of Veterinary Internal Medicine20, 1178–1183
Matus RE, Leifer CE, MacEwen EG and Hurvitz AI (1986) Prognostic factors for multiple myeloma in the dog.Journal of the American Veterinary Medical Association188, 1288–1292
Page RL, Macy DW and Thrall DE (1988) Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog.Cancer Research48, 288–290
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
